MiR-182 functions as a tumour suppressor in vitro in uveal melanoma by inhibiting cell proliferation, migration and invasion, by down-regulation of the microphthalmia-associated transcription factor and the proto-oncogene, c-Met. Here, MET is linked to neoplasm.